Allosteric Modulation of $\beta_2$-Adrenergic Receptor by Zn$^{2+}$

GAYATHRI SWAMINATH, JACQUELINE STEENHUIS, BRIAN KOBILKA, and TAE WEON LEE

Howard Hughes Medical Institute, Stanford University Medical School, Stanford, California

Received April 12, 2001; accepted September 26, 2001

ABSTRACT

Zn$^{2+}$ is abundant in the brain, where it plays a role in the function of a number of enzymes, structural proteins, and transcription factors. Zn$^{2+}$ is also found in synaptic vesicles and is released into synapses achieving concentrations in the range of 100 to 300 $\mu$M. We therefore examined the effects of Zn$^{2+}$ as a method to study G protein-coupled receptor (GPCR) function in vivo. Several groups have used Zn$^{2+}$ together with engineered metal ion binding sites as a method to study G protein-coupled receptor (GPCR) structure. However, there is considerable evidence that Zn$^{2+}$ may be a physiological regulator of receptor function. Zn$^{2+}$ is an abundant ion in the central nervous system (Schoetz et al., 1999) and may be present at high enough concentrations in specific synapses to have a physiological role in regulating GPCR function in vivo. The $\beta_2$-adrenergic receptor ($\beta_2$AR) mediates adrenergic responses in both the central nervous system and the sympathetic nervous system. We therefore examined the effects of Zn$^{2+}$ on $\beta_2$AR function. At low concentrations (1–20 $\mu$M), Zn$^{2+}$ increases agonist affinity and enhances cAMP accumulation in response to submaximal concentrations of a $\beta$-agonist. At high concentrations (>500 $\mu$M), Zn$^{2+}$ alters both $K_D$ and $B_{max}$ values for the antagonist dihydroalprenolol (DHA). These results demonstrate that Zn$^{2+}$ is a positive allosteric modulator of agonist binding for the $\beta_2$AR and suggest that Zn$^{2+}$ may be a physiologically relevant regulator of $\beta_2$AR function in vivo.

Experimental Procedures

Materials. $[^{3}H]$DHA (111.8 Ci/mmol) and guanosine-5’-O-(3-thio)triphosphate (GTP$\cdot$S; 1250 Ci/mmol) were purchased from PerkinElmer Life Sciences (Boston, MA). Unlabeled GTP$\cdot$S was purchased from Roche Molecular Biochemicals (Indianapolis, IN). GDP, zinc chloride, isoprotanol (ISO), and alprenolol were purchased from Sigma (St. Louis, MO). Nickel sulfate was obtained from Aldrich Chemical (Milwaukee, WI). Cobalt chloride was from Mallinckrodt (Chesterfield, MO). EDTA (dissodium salt) was purchased from Fisher Scientific (Fair Lawn, NJ). Baculovirus expression vector pVL1392 and BaculoGold transfection kit were obtained from BD PharMingen (San Diego, CA). SF 900 II medium was obtained from Invitrogen (Carlsbad, CA). Fetal calf serum was obtained from Gemini (Calabases, CA) and gentamicin was obtained from Roche Molecular Biochemicals (Mannheim, Germany). Glass fiber filters (GFC filters) and nitrocellulose filters were purchased from Schleicher & Schuell (Keene, NH).

Membrane Preparation. For infection, Sf9 cells were sedimented for 2 h at 1g and suspended in fresh medium. Cells were seeded at 3.0 $\times$ 10$^6$ cells/ml, infected with recombinant baculovirus for the $\beta_2$AR and/or membrane-tethered G$_\alpha_i$ (tetG$_\alpha_i$) and cultured for 48 h. All the membrane preparation steps were done at 4°C, as described elsewhere (Lee et al., 1999). Cells were harvested by centrifugation (10 min at 10,000g), washed once with phosphate-buffered saline and recentrifuged, and then resuspended in lysis buffer (10 mM Tris-HCl, pH 7.4, with 1 mM EDTA) and lysed using 25 strokes of a Dounce homogenizer. Nuclei and unbroken cells were removed by centrifugation (5 min at 500g). The supernatant was centrifuged (30 min at 40,000g). The resulting pellet was resuspended in 20 ml of lysis buffer (10 mM Tris-HCl, pH 7.4, alone) and recentrifuged. Membranes were resuspended at 0.5 to 1.5 mg of protein/ml in binding buffer (75 mM Tris-HCl, pH 7.4) and stored at −80°C until use.

ABBREVIATIONS: $\beta_2$AR, $\beta_2$-adrenergic receptor; DHA, $[^{3}H]$dihydroalprenolol; GTP$\cdot$S, guanosine-5’-O-(3-thio)triphosphate; ISO, (−)-isoprotanol; GPCR, G protein-coupled receptor; NDM, n-dodecyl maltoside; HEK, human embryonic kidney; PD 81,723, (2-amino-4,5-dimethyl-3-thieryl)-(3-(trifluoromethyl)phenyl)methanone.

This work was supported in part by National Institutes of Health grant 5R01-N526471 and the Mathers Charitable Foundation.
Urea Treatment of Membranes. Membranes were extracted with 7 M urea to remove G protein subunits (Lim and Neubig, 2001). The urea solution was prepared by dissolution of urea crystals in a buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM MgCl₂, 1 mM EDTA with protease inhibitors (25 μg/ml leupeptin and 16 μg/ml benzamidine) at room temperature and then kept on ice until use. Sf9 membranes expressing the β₂AR were pelleted (40,000g for 10 min) and resuspended to ~1 mg/ml in freshly prepared 7 M urea solution. The membranes were homogenized 10 times and incubated for 30 min with stirring. The membranes were centrifuged at 40,000g for 30 min then washed with 75 mM Tris-HCl, pH 7.4, containing protease inhibitors. The final pellet was resuspended to a final concentration of ~1 mg/ml and stored in aliquots at −80°C.

Expression and Purification of β₂AR Receptor. The human β₂AR, epitope tagged at the amino terminus with the FLAG epitope (Sigma) and tagged at the carboxy terminus with six histidines, was expressed in Sf9 cells and purified as described previously (Kobilka, 1995).

Membrane Binding Assays. Antagonist binding assays were done with membranes expressing β₂AR. Membranes (25 μg of protein) were suspended in 500 μl of binding buffer incubated with different concentrations of divalent ions in the presence of 1 nM [³H]DHA. Saturation binding experiments were done on the β₂AR expressed in Sf9 membranes. Membranes (50 μg of protein) were suspended in 500 μl of binding buffer supplemented with 100 pM to 10 nM [³H]dihydroalprenolol and 0.2% bovine serum albumin. The binding buffer contained only 75 mM Tris-HCl, pH 7.5. Nonspecific binding was assessed with 10 μM alprenolol. Incubations were performed for 1 h at room temperature with shaking at 230 rpm. Competition binding experiments were carried out with 1 nM [³H]dihydroalprenolol in the presence of increasing concentrations of (−)-isoproterenol and different concentrations of divalent ions.

Solubilized Binding Assays. Binding assays on purified, detergent-solubilized receptor were carried out in 100-μl volumes in high-salt buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, and 0.1% n-dodecyl maltoside). The binding assays were stopped and free [³H]DHA separated from bound by desalting on 2-ml Sephadex G50 column (4 × 0.5 cm) by using ice-cold high-salt buffer. Non-specific binding was determined in the presence of 10 μM alprenolol.

Dissociation Rate Kinetic Assay. The effect of zinc on the rate of antagonist dissociation from β₂AR was examined by measuring the kₜ-turnover constant, in the absence and presence of 1 mM Zn²⁺. Membranes were suspended in 75 mM Tris-HCl, pH 7.5, with 1 nM [³H]DHA for 30 min at room temperature (shaking at 230 rpm). At time zero, total binding was determined and a saturating amount of cold alprenolol (final 10⁻⁵ M) or cold alprenolol (final 10⁻⁷ M) and ZnCl₂ (final concentration, 1 mM) was added to tubes containing membranes and [³H]DHA. Bound [³H]DHA was measured at 5-min intervals.

[³⁵S]GTPγS Binding. β₂AR with tetGₛ was coexpressed in Sf9 cells and membranes were prepared as described above. Membranes were pelleted by a 15-min centrifugation at 4°C at 15,000g and resuspended in buffer containing 75 mM Tris-HCl, pH 7.5. Sf9 membranes (10 μg of protein/tube) were suspended in 500 μl of magnesium binding buffer (75 mM Tris-HCl, pH 7.5, and 1 mM MgCl₂) supplemented with 0.05% (w/v) bovine serum albumin, 1 nM [³⁵S]GTPγS (0.25 μCi/tube), 1 μM GDP with or without 10 μM isoproterenol in presence or absence of Zn²⁺. Incubations were performed at 25°C and shaking at 250 rpm for 1 h. Nonspecific binding was determined in the presence of 10 μM GTPγS and was less than 0.2% of total binding. Bound [³⁵S]GTPγS was separated from free [³⁵S]GTPγS by filtration through GF/C filters, followed by three washes with 3 ml of cold magnesium binding buffer. Filter-bound radioactivity was determined by liquid scintillation counting.

cAMP Accumulation. The production of cAMP was determined by adenyl cyclase activation FlashPlate assay (PerkinElmer Life Sciences), in which 96-well plates are coated with solid scintillant to which anti-cAMP antibody has been bound. Briefly, HEK293 cells expressing human β₂AR were detached and washed four times in 1× phosphate-buffered saline without Ca²⁺/Mg²⁺, and then resuspended to a density of approximately 2 × 10⁶ cells/ml in stimulation buffer (1× phosphate-buffered saline, without calcium/magnesium, with 700 μM 3-isobutyl-1-methylxanthine, 0.1% protease-free bovine serum albumin, and 0.09% chloroacetamide) from PerkinElmer Life Sciences. Ligands (25 μl each) were diluted in Milli-Q water with various concentrations and dispensed to the flashplate. Resuspended whole cells (50 μl) were added to the ligand-loaded plate and stimulated at 37°C for 10 min before lysing cells with 100 μl of Detection Buffer (Invitrogen) containing 125I-cAMP, permeabilizer, and 0.09% sodium azide as provided by the manufacturer. After 2 h of incubation at room temperature, radioactivity was counted. To determine the concentrations of cAMP in the sample, cAMP standards were run in the same plate and expressed as picomoles per well.

Miscellaneous. Protein was determined using the DC protein assay kit (Bio-Rad, Hercules, CA). Data were analyzed by nonlinear regression analysis with Prism program (GraphPad Software, San Diego, CA).

Results

Effect of Zn²⁺ on Antagonist Binding. To examine the effect of Zn²⁺ on antagonist binding, we performed radioligand binding studies by using [³H]DHA, a neutral antagonist. As shown in Fig. 1A, a significant effect of Zn²⁺ on DHA binding was observed only at concentrations of Zn²⁺ >500 μM, where DHA binding was reduced by 40 ± 2% (Fig. 1A). Saturation binding studies in the presence or absence of 1 mM Zn²⁺ caused an increase of nearly 3-fold in apparent Kᵢᵣ value for DHA (1.4 ± 0.2 nM control, 4.9 ± 1.2 nM with Zn²⁺ ) with a 40% decrease in B_max (Fig. 1B). These results suggest that Zn²⁺ may function as a non-competitive blocker of antagonist binding; however, we found that 1 mM Zn²⁺ slowed the rate of DHA dissociation (Fig. 1C). Moreover, the effect of Zn²⁺ on antagonist binding is not fully reversible in membrane-bound β₂AR (Fig. 2A). Note that Zn²⁺ also inhibits binding of antagonist to purified, detergent-solubilized β₂AR; however, this inhibition is almost completely reversible after chelation of Zn²⁺ by EDTA (Fig. 2B). These results suggest that some of the effects of Zn²⁺ on antagonist binding may be caused by nonspecific effects of Zn²⁺ on phospholipids.

Effect of Zn²⁺ on High- and Low-Affinity Agonist Binding. We examined the effect of Zn²⁺ on agonist binding in membranes expressing the β₂AR with and without Gₛₛ. For these experiments, we used tetGₛₛ. We have shown previously that tetGₛₛ couples more efficiently to β₂AR than does wild-type Gₛₛ (Lee et al., 1999). In membranes expressing the β₂AR with tetGₛₛ, we observed a biphasic curve with a high-affinity, GTPγS-sensitive component (Fig. 3). To study the effect of Zn²⁺ on agonist binding affinity, isoproterenol competition binding studies were done using 1 nM antagonist [³H]DHA in the presence of varying concentrations of Zn²⁺ (Fig. 4, A–C). As shown in Fig. 4A, as little as 20 μM Zn²⁺ resulted in a change of the apparent biphasic nature of the competition curve with an increase in Kᵢᵣ. We also observed a decrease in Kᵢᵣ.
which was even greater at 100 μM Zn²⁺ (Fig. 4B), a concentration at which we observed no effects on antagonist binding. A smaller decrease in $K_L$ was observed at 1 mM Zn²⁺ (Fig. 4C), a concentration that also reduces antagonist affinity. We observed similar effects on agonist binding affinity in membranes expressing a β₂AR without tetGs, where only a small amount of high-affinity binding is detected (Fig. 5A), as well as in membranes treated with 7 M urea to remove heterotrimeric G proteins (Fig. 5B). Thus, at relatively low concentrations, Zn²⁺ induces an increase in agonist affinity for the uncoupled receptor.

The receptor used in the studies described thus far contains a hexahistidine tail on the carboxyl terminus to facilitate receptor purification. However, we observed identical effects of Zn²⁺ on antagonist binding (data not shown) and on agonist binding in membranes expressing a β₂AR without a carboxyl-terminal hexahistidine sequence (Fig. 5C). Therefore, binding of Zn²⁺ to this carboxyl-terminal hexahistidine sequence is not responsible for the observed effects of Zn²⁺ on receptor function.

To further investigate the effect of Zn²⁺ on the GTPγS-insensitive agonist binding affinity, we performed a modified competition binding experiment in which 100 nM isoproterenol competes for binding sites with 1 nM [³H]DHA in the presence of 10 μM GTPγS and varying concentrations of Zn²⁺ (Fig. 6A). Also shown is the effect of Zn²⁺ on [³H]DHA binding in the absence of isoproterenol. In the presence of increasing concentrations of Zn²⁺, 100 nM isoproterenol becomes more effective at displacing [³H]DHA. The maximal effect of Zn²⁺ on isoproterenol affinity occurs at ~30 μM with an IC₅₀ of 3.0 μM. Similar results were obtained with membranes that had been extracted with 7 M urea to remove G proteins (Fig. 6B).
To confirm that the Zn$^{2+}$-mediated increase in agonist affinity was caused by a direct interaction between Zn$^{2+}$ and the $\beta_2$AR, we examined the influence of Zn$^{2+}$ on purified, detergent-solubilized $\beta_2$AR. As shown in Fig. 6C, Zn$^{2+}$ enhanced the ability of 1 $\mu$M isoproterenol to displace [$^3$H]DHA in a soluble binding assay.

**Effects of Ni$^{2+}$ and Co$^{2+}$ on Agonist and Antagonist Binding.** To determine the specificity of the functional effects of Zn$^{2+}$ on receptor function we compared the effect of Ni$^{2+}$ and Co$^{2+}$ on agonist and antagonist binding (Fig. 7). Co$^{2+}$ had an effect on agonist affinity similar to Zn$^{2+}$, but no significant effect on antagonist affinity (Fig. 7A). Ni$^{2+}$ had no significant effect on either agonist or antagonist affinity (Fig. 7B).

**Inhibition of Gs Function by Zn$^{2+}$.** Our competition binding studies (Fig. 4) suggest that Zn$^{2+}$ uncouples the receptor from Gs. To further examine the effect of Zn$^{2+}$ on the interaction of the $\beta_2$AR and Gs, receptor-mediated GTP$\gamma$S binding was performed in Sf9 membranes coexpressing $\beta_2$AR and tetGs. Consistent with the results of Sheikh et al. (1999), we found that Zn$^{2+}$ inhibited stimulation of GTP$\gamma$S binding by the agonist isoproterenol with an IC$_{50}$ of 7.2 $\mu$M (Fig. 8). However, we also found that Zn$^{2+}$ inhibited basal GTP$\gamma$S binding to purified Gs, (data not shown), suggesting that the uncoupling of $\beta_2$AR and Gs is caused by a direct effect of Zn$^{2+}$ on Gs, possibly by competing for the Gs$^{2+}$ binding site.

**Effect of Zn$^{2+}$ on Isoproterenol-Stimulated cAMP Accumulation.** The studies described above were done on membrane fragments or purified receptor in which Zn$^{2+}$ has equal access to both cytoplasmic and extracellular domains of the $\beta_2$AR. Therefore, they do not provide information about the location of the Zn$^{2+}$ binding site(s) responsible for the functional effects of Zn$^{2+}$ on agonist and antagonist binding. In vivo, Zn$^{2+}$ released from synaptic vesicles would have access to extracellular domains of the receptor. Diffusion or transport of Zn$^{2+}$ across the plasma membrane would limit access to intracellular domains. We therefore examined the effect of Zn$^{2+}$ on isoproterenol-stimulated cAMP accumulation in intact HEK293 cells expressing the wild-type (non–histidine-tagged) $\beta_2$AR. Isoproterenol dose-response studies revealed that at Zn$^{2+}$ concentrations 100 $\mu$M or greater the maximal cAMP accumulation was decreased (Fig. 9A). When these data were plotted as the percentage of the maximal isoproterenol-stimulated cAMP, we observed a small decrease in EC$_{50}$ in the presence of 1 $\mu$M Zn$^{2+}$ (Fig. 9B). To further examine the effect of Zn$^{2+}$ on isoproterenol-stimulated cAMP accumulation, cells were exposed to increasing concentrations of Zn$^{2+}$ in the presence of 0 to 1 nM isoproterenol. Maximal cAMP accumulation was observed at 1 $\mu$M Zn$^{2+}$ in the absence of isoproterenol, but Zn$^{2+}$ had no effect in the absence of isoproterenol (Fig. 9C). Moreover, Zn$^{2+}$ did not

---

**Fig. 3.** Effect of GTP$\gamma$S on isoproterenol competition of DHA binding to Sf9 membranes expressing $\beta_2$AR together with tetGs. Isoproterenol competition in presence and absence of unlabeled GTP$\gamma$S (10 $\mu$M) was performed as described under Experimental Procedures. Reaction mixtures contained 10 $\mu$g of protein/tube. The membranes expressing the protein were 15.7 pmol/mg. Data shown are the mean ± S.D. of three independent experiments performed in triplicate. Binding data were analyzed for best fit to two affinity states.

**Fig. 4.** Modulation of agonist binding by Zn$^{2+}$. A to C, isoproterenol competition binding was performed on membranes expressing $\beta_2$AR (12.7 pmol/mg) together with tetGs, in the presence of 20 $\mu$M Zn$^{2+}$ (A), 100 $\mu$M Zn$^{2+}$ (B), and 1 nM Zn$^{2+}$ (C). The antagonist binding observed in the absence of any competitor was set to 100%. In A to C, binding in the absence of Zn$^{2+}$ is shown for reference. In the presence of 20 to 100 $\mu$M Zn$^{2+}$, GTP$\gamma$S-sensitive high-affinity binding is lost, yet the affinity of the low-affinity binding is increased. Reaction mixtures contained 1 nM [$^3$H]DHA and isoproterenol at the indicated concentrations. Binding data were analyzed for best fit to two affinity states. Data represent the mean of three independent experiments. Each experiment was performed in triplicate.
augment cAMP accumulation stimulated by either 10 or 100 μM forskolin (Fig. 9D).

**Discussion**

Our results demonstrate that at micromolar concentrations, Zn$^{2+}$ is a positive allosteric modulator of agonist binding; at higher concentrations, Zn$^{2+}$ has complex effects on antagonist binding. Allosteric modulation of ligand binding has been observed for several GPCRs. These modulators include physiologically relevant ions as well as small organic molecules. A large number of compounds allosterically increase binding affinity for muscarinic receptor antagonists. Allosteric regulation can be demonstrated in all five subtypes of muscarinic receptors, but the m2 receptor seems to be the most sensitive (Tucek and Proska, 1995). Although most allosteric modulators for the muscarinic receptors primarily affect antagonist binding, allosteric modulation of agonist binding has also been described previously (Jakubik et al., 1997).

In addition to the muscarinic receptor, allosteric compounds have been identified for the A1 adenosine receptor. The 2-amino-3-benzoylthiophene PD 81,723 has been shown to enhance agonist binding and G protein coupling in a Mg$^{2+}$-dependent manner (Bhattacharya and Linden, 1995; Musser et al., 1999).

![Fig. 5. Effect of Zn$^{2+}$ on agonist binding does not depend on Gs. A, effect of 20 μM Zn$^{2+}$ on agonist binding affinity in Sf9 membranes expressing β2AR without tetGon. Isoproterenol competition binding experiments were performed as described under Experimental Procedures. The competition binding was performed with 1 nM [3H]DHA in the presence of different concentrations of isoproterenol with and without 20 μM Zn$^{2+}$. B, competition binding experiments performed on membranes treated with 7 M urea to remove G proteins. Urea treatment of membranes is described under Experimental Procedures. Experiments shown in A and B above were done on membranes expressing the β2AR with a carboxy-terminal hexahistidine sequence. C, effect of 20 μM Zn$^{2+}$ on agonist binding affinity in membranes expressing β2AR without a carboxy-terminal His tag. Data represent the mean of two independent experiments. Each experiment was done in triplicate.](image)

![Fig. 6. Effect of zinc on the agonist affinity. A, effect of Zn$^{2+}$ on [3H]DHA binding in presence and absence of 100 nM isoproterenol was determined using Sf9 membranes expressing β2AR (7 pmol/mg). Assay mixtures contained ~25 μg of membrane protein, 1 nM [3H]DHA, and 10 μM GTPγS. Nonspecific binding was less than 10% of total binding. Data represent the mean ± S.D. of three independent experiments. Each of these experiments was performed in triplicate. B, effect of Zn$^{2+}$ on agonist affinity in urea-treated membranes expressing β2AR (12.6 pmol/mg). The reaction mixtures contained ~20 μg of membrane protein and 2 nM [3H]DHA. Data represent the mean ± S.D. of two independent experiments. Each of these experiments was performed in triplicate. C, effect of Zn$^{2+}$ on agonist affinity in purified, detergent-solubilized β2AR. Soluble binding was performed as described under Experimental Procedures. The assay mixture contained purified receptor, with or without 1 μM isoproterenol, and 2 nM [3H]DHA, in the absence or presence of the indicated concentrations of zinc. Data obtained were from three independent experiments done in duplicate. All the binding data were analyzed for best fit to two affinity states.](image)
The function of several Gi-coupled receptors has been shown to be modulated by amiloride analogs and by Na\(^+\). This effect has been particularly well characterized for the \(\alpha_{2a}\)-adrenergic receptor (Motulsky and Insel, 1983; limbird, 1984; Horstman et al., 1990) and for the dopamine D2 (Neve, 1991) and D4 subtypes (Schetz and Sibley, 2001). Na\(^+\) both uncouples the receptor from Gi and reduces agonist affinity. The Na\(^+\)-sensitive site has been identified in the \(\alpha_{2}\)-adrenergic receptor (Horstman et al., 1990) and the D4 dopamine receptor (Schetz and Sibley, 2001) as a conserved Asp residue within the cytoplasmic side of transmembrane 2. This Na\(^+\) sensitivity may be physiologically relevant, because relatively high local concentrations may be achieved near the cytoplasmic side of the receptor after membrane depolarization.

Recently, the function of the calcium receptor has been shown to be positively modulated by certain L-amino acids (Conigrave et al., 2000a,b). This may be physiologically relevant because nutrient and Ca\(^{2+}\) homeostasis may be regulated in a coordinate manner.

Zn\(^{2+}\) is an abundant divalent cation in the central nervous system and is released from some synaptic vesicles (Schetz et al., 1999; Weiss et al., 2000). Zn\(^{2+}\) has been shown to be a noncompetitive blocker of dopamine uptake by the dopamine transporter (Norregaard et al., 1998) and modulates the function of several ligand-gated ion channels. Glycine-induced currents in freshly dissociated rat dorsal motor nucleus neurons are potentiated at low concentrations of Zn\(^{2+}\) (<3 \(\mu\)M) but inhibited at higher concentrations (>10 \(\mu\)M) (Doi et al., 1999). Zn\(^{2+}\) inhibits \(\gamma\)-aminobutyric currents by slowing the transition rate from closed to open and by accelerating the deactivation kinetics (Barberis et al., 2000). Of particular interest is the observation that relatively low concentrations of Zn\(^{2+}\) (~10 \(\mu\)M) potentiate both agonist binding and peak current in the 5-hydroxytryptamine 3 receptor (Hubbard and Lummis, 2000).

Less is known about the regulation of G protein-coupled receptor function by Zn\(^{2+}\). At relatively high concentrations (>100 \(\mu\)M), Zn\(^{2+}\) has been shown to inhibit antagonist binding to the dopamine receptor (D1, D2, and D4 subtypes) (Schetz and Sibley, 1997, 2001). However, the effect of Zn\(^{2+}\) on agonist binding or G protein activation was not examined. In the case of the D4 dopamine receptor, the Zn\(^{2+}\) binding site that alters antagonist binding is different from the Na\(^+\) binding site (Schetz and Sibley, 2001). Zn\(^{2+}\) at high concentrations (>1 mM) also inhibits binding to the M1 muscarinic receptor (Thirstrup et al., 1996). However, to our knowledge, there has been no report of Zn\(^{2+}\) increasing agonist affinity at these or other GPCRs.

Our findings with the human \(\beta_2\)AR constitute the first report of Zn\(^{2+}\) as a positive allosteric modulator of agonist binding for a GPCR. The effect of Zn\(^{2+}\) on agonist binding is caused by a direct effect of Zn\(^{2+}\) on the \(\beta_2\)AR, because it was observed in membranes treated with 7 M urea, a concentration shown previously to strip membranes of both \(\alpha\) and \(\beta\) G protein subunits (Lim and Neubig, 2001) (Fig. 5B). Moreover, we observed that Zn\(^{2+}\) enhanced agonist affinity in purified \(\beta_2\)AR (Fig. 6B).

While enhancing agonist affinity, Zn\(^{2+}\) seems to uncouple the receptor from Gs, probably due to a direct effect of Zn\(^{2+}\) on Gs, because Zn\(^{2+}\) inhibited basal GTP\(\gamma\)S binding to puri-
Allosteric Modulation of βAR by Zn^{2+}

Zn^{2+} has been extensively studied for its impact on receptor signaling, particularly with regard to β-receptors. This divalent cation binds to a high-affinity site on Gs, which is inhibitory and may explain the inhibition of cAMP accumulation mediated by Gs (data not shown). GTP binds to Gs as a GTP-Mg^{2+} complex (Birnbaumer and Birnbaumer, 1995). Zn^{2+} may form a complex with GTP or interact directly with the Mg^{2+} binding site on Gs. However, in intact cells, we observed a small increase in isoproterenol-stimulated cAMP accumulation (Fig. 9B). This stimulatory effect of Zn^{2+} on cAMP accumulation is most probably caused by a direct effect of Zn^{2+} on the β_{2}AR, rather than on downstream signaling components, for several reasons. The plasma membrane limits access of Zn^{2+} to intracellular signaling components. We observe no effect of Zn^{2+} in the absence of the β-agonist. As discussed above, the effect of Zn^{2+} on Gs is inhibitory and occurs at Zn^{2+} concentrations greater than 1 μM. This inhibitory effect may explain the inhibition of cAMP accumulation that we observe at higher Zn^{2+} concentrations (Fig. 9). Moreover, Zn^{2+} has been reported to be an inhibitor of adenyl cyclase (Tesmer et al., 1999). Finally, the cAMP accumulation experiments were done in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, and Zn^{2+} did not augment cAMP-stimulated by forskolin (Fig. 9D). Therefore, the effect of Zn^{2+} cannot be explained by inhibition of CAMP hydrolysis. Therefore, we would predict that the Zn^{2+} enhances cAMP accumulation by an interaction with an extracellular domain of the β_{2}AR, possibly the same domain responsible for the positive allosteric effect on agonist binding.

The effect of Zn^{2+} on antagonist binding seems to be biphasic (Figs. 1A and 5A). A small (<20%) decrease in antagonist binding occurs with an IC_{50} comparable with that for the Zn^{2+} effect on agonist affinity (~5 μM; Fig. 5A); however, a larger effect is observed at concentrations >100 μM. At 1 mM Zn^{2+}, both B_{max} and K_{D} values for [^{3}H]DHA binding are altered, consistent with the idea that Zn^{2+} is a noncompetitive blocker of this antagonist. However, Zn^{2+} also slows the rate of [^{3}H]DHA dissociation (Fig. 1C), and the effects of 1 mM Zn^{2+} on antagonist binding are not fully reversible in membrane-bound receptor (Fig. 2A). The fact that binding is almost completely reversible in purified, detergent-soluble receptor suggests that some of the effects of Zn^{2+} on agonist binding may be caused by interactions between Zn^{2+} and phospholipids. Previous studies showed that Zn^{2+} can alter the properties of phospholipids by interactions with the polar head groups (Binder et al., 2001). Thus, the effects of Zn^{2+} on antagonist binding are complex and cannot be explained by noncompetitive inhibition. However, because these effects occur only at relatively high concentrations of Zn^{2+} (>100 μM), they are not likely to be physiologically important.

Our results are consistent with the existence of at least two Zn^{2+} binding sites in the β_{2}AR, one primarily affecting agonist binding and one primarily affecting antagonist binding. This is further supported by the differential effects of other divalent cations on agonist and antagonist binding. Like Zn^{2+}, Co^{2+} enhances agonist binding but has no significant effect on antagonist binding (Fig. 7A). Ni^{2+} has only a small effect on antagonist binding, but no significant effect on agonist binding (Fig. 7B). Thus, the divalent cation binding site influencing agonist binding can accommodate Zn^{2+} and Co^{2+}, but not Ni^{2+}, whereas the binding site influencing antagonist binding accommodates Zn^{2+} and to a much lesser extent Ni^{2+}, but not Co^{2+}.

In conclusion, Zn^{2+} has complex effects on the functional properties of the β_{2}AR. Zn^{2+} binding to a high affinity site (IC_{50} of ~5 μM) enhances agonist affinity and agonist-stimulated cAMP accumulation. Zn^{2+} binding to a low-affinity site (IC_{50} of >500 μM) inhibits antagonist binding, yet slows antagonist dissociation. The effects of Zn^{2+} on agonist binding and cAMP accumulation occur at concentrations of Zn^{2+} that may be achieved within a synapse.

**Fig. 9.** Effect of zinc on isoproterenol-stimulated cAMP accumulation in HEK293 cells. A, ISO dose-response studies were done in HEK293 cells expressing nonhistidine-tagged β_{2}AR in the presence of 0, 1, and 1000 μM Zn^{2+}. The cAMP assay was performed as described under Experimental Procedures. B, data in A replotted as the percentage of the maximal cAMP response. C, Zn^{2+} dose-response studies done in the presence of 0, 0.1, 0.3, 0.6, and 1 mM ISO. D, Zn^{2+} dose-response studies done in the presence of 10 and 100 μM forskolin. Data represented are from three independent experiments performed in triplicate.
Thus, Zn\(^{2+}\) may be a physiological modulator of \(\beta_2\)AR function.

References


